ADARx raised about $602.5 million, expects cash to last into 2030, advanced 3 Phase 2 trials, and received FDA Fast Track status. Research spending also rose to $26.7 million from $19.4 million, but the funding and clinical progress support a stronger outlook.
That cash gives ADARx more time to develop its drug candidates. Three agazisiran trials advanced into Phase 2, and onvuzosiran received FDA Fast Track status. Research spending climbed from $19.4 million to $26.7 million as the company invested in candidates and staff. That higher cost is a concern, but the cash and clinical progress make the report favorable.
The report says the agreement with AbbVie produced revenue for ADARx, but gives no change in AbbVie’s sales, costs, or agreement terms.
Follow ADARx Pharmaceuticals (ADRX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ADRX